Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

ARA-290Explore study findings

Why a sarcoidosis trial photographed nerves in the cornea

2 numbered sourcesSource years 2017, 2026

Peptides are short amino-acid chains connected by peptide bonds. Some can mimic part of a signal made by the body. ARA-290, or cibinetide, is a synthetic 11-amino-acid peptide designed to engage a proposed tissue-protection signaling pathway. Researchers studying small nerve fibers in sarcoidosis needed a way to measure tissue changes in living people. They used a microscope that can visualize nerve branches in the cornea. [1]

A 2026 study in a separate population shows how the method can be used. Investigators examined corneal nerve density, length and branching in 80 adults with type 2 diabetes. Several measures were associated with diabetes duration, glucose control and signs of nerve or vascular dysfunction. This was an observational study and did not test cibinetide. It illustrates that corneal imaging can describe small nerve fibers and be compared with other measures of health. An association at one point in time cannot tell whether the measurement will change after a particular intervention. [2]

The older 2017 sarcoidosis study tested the peptide directly. It randomly assigned 64 people with sarcoidosis-associated small nerve fiber loss and neuropathic pain among three cibinetide groups and placebo. The primary outcome was the change in the area covered by corneal nerve fibers after 28 days. One cibinetide group showed a statistically significant increase compared with placebo. That group also showed an increase in fibers bearing a marker associated with nerve growth in a skin biopsy. The cornea and skin measurements came from two distinct tissues and gave researchers a way to compare their response. [1]

Pain ratings improved across the groups, including placebo. A comparison in participants with moderate to severe pain favored one cibinetide group numerically but fell short of statistical significance. Some changes in the nerve measures were correlated with changes in walking distance. A correlation can help motivate a larger study, but it cannot establish that the tissue change caused a functional improvement. Each clinical outcome needs its own adequately sized comparison. [1]

Corneal imaging is attractive because researchers can repeat it without collecting tissue from the eye. It tells them how the pattern of small fibers looks in a specific, accessible site. Skin biopsies can add information from another site. The trial supports a measurable short-term difference in certain tissue markers. Evidence about durable changes in symptoms, walking or the course of the disease would require follow-up and outcomes designed for those questions. That is the difference between measuring a promising marker and showing what a person experiences over time. [1] [2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop ARA-290

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.